NCT00306566View on ClinicalTrials.gov

Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

CYT004-MelQbG10

Trial Locations (1)

1011

Centre Pluridisciplinaire d'Oncologie & LICR, CHUV, Lausanne

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY

NCT00306566 - Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients | Biotech Hunter | Biotech Hunter